APA (7th ed.) Citation

Lin, W., Kuo, F., Li, Y., Yeh, H., Chang, W., Wu, Y., . . . Lin, T. (2023). Real-World Analyses of the Treatment Conditions in Patients Initiating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor in Taiwan. Journal of Atherosclerosis and Thrombosis, 30(9), 1123-1131. https://doi.org/10.5551/jat.63789

Chicago Style (17th ed.) Citation

Lin, Wei-Wen, et al. "Real-World Analyses of the Treatment Conditions in Patients Initiating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor in Taiwan." Journal of Atherosclerosis and Thrombosis 30, no. 9 (2023): 1123-1131. https://doi.org/10.5551/jat.63789.

MLA (9th ed.) Citation

Lin, Wei-Wen, et al. "Real-World Analyses of the Treatment Conditions in Patients Initiating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor in Taiwan." Journal of Atherosclerosis and Thrombosis, vol. 30, no. 9, 2023, pp. 1123-1131, https://doi.org/10.5551/jat.63789.